TriSalus Life Sciences has announced the launch of the TriNav FLX infusion system.
The TriNav FLX infusion system retains the same trusted pressure-enabled drug delivery (PEDD) benefits as existing products but introduces an important advancement in design, states a recent company press release. The new system features twice the length of flexible material at the distal end, allowing for easier navigation through more tortuous vessels.
Key features of the TriNav FLX infusion system include:
- Trackability: The more flexible distal end provides improved navigation through challenging pathways
- Reduction in Force: In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard TriNav design
“We’re excited to further expand our TriNav portfolio with the introduction of the TriNav FLX infusion system,” said Mary Szela, chief executive officer of TriSalus Life Sciences.
“With TriNav FLX, we now offer a comprehensive suite of advanced technologies designed to support interventional radiologists in navigating a wide range of peripheral vessel sizes and complexities. Our continued investment in portfolio innovation underscores our commitment to making pressure-enabled drug delivery accessible to more patients. Importantly, TriNav FLX is also eligible for reimbursement under HCPCS Code C8004 for simulation—or mapping—as well as C9797 for treatment procedures. This dual coverage allows clinicians to use TriNav FLX for both planning and delivery in radioembolization, supporting greater precision and continuity of care.”
